Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 65.23 kDa 
• Atom Count: 4594 
• Modelled Residue Count: 551 
• Deposited Residue Count: 551 
• Unique protein chains: 1

1EBV

OVINE PGHS-1 COMPLEXED WITH SALICYL HYDROXAMIC ACID

• DOI: 10.2210/pdb1EBV/pdb

• Classification: OXIDOREDUCTASE
• Organism(s): Ovis aries
• Mutation(s): Yes 


• Deposited: 2000-01-24 Released: 2000-02-24 
• Deposition Author(s): Loll, P.J., Sharkey, C.T., O'Connor, S.J., Fitzgerald, D.J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 3.20 Å
• R-Value Free: 0.248 
• R-Value Work: 0.218 
• R-Value Observed: 0.225 

Literature

O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme-inhibitor interactions.

Loll, P.J., Sharkey, C.T., O'Connor, S.J., Dooley, C.M., O'Brien, E., Devocelle, M., Nolan, K.B., Selinsky, B.S., Fitzgerald, D.J.

(2001) Mol Pharmacol 60: 1407-1413

• PubMed: 11723249 
• DOI: 10.1124/mol.60.6.1407
• Primary Citation of Related Structures:  
  1EBV


• PubMed Abstract: 
  

Aspirin is unique among clinically used nonsteroidal antiinflammatory drugs in that it irreversibly inactivates prostaglandin (PG) H2 synthase (PGHS) via acetylation of an active-site serine residue. We report the synthesis and characterization of a novel acetylating agent, O-acetylsalicylhydroxamic acid (AcSHA), which inhibits PGE2 synthesis in vivo and blocks the cyclooxygenase activity of PGHS in vitro. AcSHA requires the presence of the active-site residue Ser-529 to be active against human PGHS-1; the S529A mutant is resistant to inactivation by the inhibitor. Analysis of PGHS inactivation by AcSHA, coupled with the X-ray crystal structure of the complex of ovine PGHS-1 with AcSHA, confirms that the inhibitor elicits its effects via acetylation of Ser-529 in the cyclooxygenase active site. The crystal structure reveals an intact inhibitor molecule bound in the enzyme's cyclooxygenase active-site channel, hydrogen bonding with Arg-119 of the enzyme. The structure-activity profile of AcSHA can be rationalized in terms of the crystal structure of the enzyme-ligand complex. AcSHA may prove useful as a lead compound to facilitate the development of new acetylating inhibitors.

---

Organizational Affiliation: 

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
PROSTAGLANDIN H2 SYNTHASE	A	551	Ovis aries	Mutation(s): 1  Gene Names: PTGS1, COX1 EC: 1.14.99.1
UniProt
Find proteins for P05979 (Ovis aries) Explore P05979  Go to UniProtKB:  P05979

Oligosaccharides

Help

Entity ID: 2
Molecule	Chains	Chain Length	2D Diagram	Glycosylation
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose	B	2		N-Glycosylation
Glycosylation Resources
GlyTouCan:  G42666HT GlyCosmos:  G42666HT GlyGen:  G42666HT

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
HEM (Subject of Investigation/LOI)	F [auth A]	PROTOPORPHYRIN IX CONTAINING FE C34 H32 Fe N4 O4 KABFMIBPWCXCRK-RGGAHWMASA-L
NAG (Subject of Investigation/LOI)	C [auth A], D [auth A]	2-acetamido-2-deoxy-beta-D-glucopyranose C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N
SCL (Subject of Investigation/LOI)	E [auth A]	ACETIC ACID SALICYLOYL-AMINO-ESTER C9 H9 N O4 PCFWLDHLJWUGSU-UHFFFAOYSA-N

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
OAS	A	L-PEPTIDE LINKING	C5 H9 N O4		SER

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 3.20 Å
• R-Value Free: 0.248 
• R-Value Work: 0.218 
• R-Value Observed: 0.225 
• Space Group: I 2 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 98.87	α = 90
b = 207.46	β = 90
c = 221.98	γ = 90

Software Package:

Software Name	Purpose
MAR345	data collection
SCALEPACK	data scaling
X-PLOR	model building
CNS	refinement
X-PLOR	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2000-01-24 
• Released Date: 2000-02-24 
Deposition Author(s): Loll, P.J., Sharkey, C.T., O'Connor, S.J., Fitzgerald, D.J.

Revision History  

• Version 1.0: 2000-02-24
  Type: Initial release
  
• Version 1.1: 2008-04-27
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Non-polymer description, Version format compliance
• Version 1.3: 2017-10-04
  Changes: Refinement description
• Version 2.0: 2020-07-29
  Type: Remediation
  Reason: Carbohydrate remediation
  Changes: Atomic model, Data collection, Database references, Derived calculations, Structure summary